Chung Hsin-Pei, Tang Yen-Hsiang, Chen Chun-Yen, Chen Chao-Hsien, Chang Wen-Kuei, Kuo Kuan-Chih, Chen Yen-Ting, Wu Jou-Chun, Lin Chang-Yi, Wang Chieh-Jen
Division of Pulmonary, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan.
Department of Critical Care Medicine, MacKay Memorial Hospital, Taipei, Taiwan.
Front Med (Lausanne). 2023 Feb 8;10:1121465. doi: 10.3389/fmed.2023.1121465. eCollection 2023.
The aim of our study was to externally validate the predictive capability of five developed coronavirus disease 2019 (COVID-19)-specific prognostic tools, including the COVID-19 Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), Shang COVID severity score, COVID-intubation risk score-neutrophil/lymphocyte ratio (IRS-NLR), inflammation-based score, and ventilation in COVID estimator (VICE) score.
The medical records of all patients hospitalized for a laboratory-confirmed COVID-19 diagnosis between May 2021 and June 2021 were retrospectively analyzed. Data were extracted within the first 24 h of admission, and five different scores were calculated. The primary and secondary outcomes were 30-day mortality and mechanical ventilation, respectively.
A total of 285 patients were enrolled in our cohort. Sixty-five patients (22.8%) were intubated with ventilator support, and the 30-day mortality rate was 8.8%. The Shang COVID severity score had the highest numerical area under the receiver operator characteristic (AUC-ROC) (AUC 0.836) curve to predict 30-day mortality, followed by the SEIMC score (AUC 0.807) and VICE score (AUC 0.804). For intubation, both the VICE and COVID-IRS-NLR scores had the highest AUC (AUC 0.82) compared to the inflammation-based score (AUC 0.69). The 30-day mortality increased steadily according to higher Shang COVID severity scores and SEIMC scores. The intubation rate exceeded 50% in the patients stratified by higher VICE scores and COVID-IRS-NLR score quintiles.
The discriminative performances of the SEIMC score and Shang COVID severity score are good for predicting the 30-day mortality of hospitalized COVID-19 patients. The COVID-IRS-NLR and VICE showed good performance for predicting invasive mechanical ventilation (IMV).
我们研究的目的是对外验证五种已开发的2019冠状病毒病(COVID-19)特异性预后工具的预测能力,包括COVID-19西班牙传染病和临床微生物学会(SEIMC)评分、尚氏COVID严重程度评分、COVID-插管风险评分-中性粒细胞/淋巴细胞比值(IRS-NLR)、基于炎症的评分以及COVID通气估计器(VICE)评分。
对2021年5月至2021年6月期间因实验室确诊的COVID-19诊断而住院的所有患者的病历进行回顾性分析。在入院的前24小时内提取数据,并计算五种不同的评分。主要和次要结局分别为30天死亡率和机械通气。
我们的队列共纳入285例患者。65例患者(22.8%)接受了呼吸机支持下的插管,30天死亡率为8.8%。尚氏COVID严重程度评分在预测30天死亡率的受试者操作特征曲线下面积(AUC-ROC)数值最高(AUC 0.836),其次是SEIMC评分(AUC 0.807)和VICE评分(AUC 0.804)。对于插管,与基于炎症的评分(AUC 0.69)相比,VICE和COVID-IRS-NLR评分的AUC最高(AUC 0.82)。根据较高的尚氏COVID严重程度评分和SEIMC评分,30天死亡率稳步上升。在按较高的VICE评分和COVID-IRS-NLR评分五分位数分层的患者中,插管率超过50%。
SEIMC评分和尚氏COVID严重程度评分在预测住院COVID-19患者的30天死亡率方面具有良好的鉴别性能。COVID-IRS-NLR和VICE在预测有创机械通气(IMV)方面表现良好。